INmune Bio Stock (NASDAQ:INMB), Trade Ideas

INmune Bio

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

doctor-3822863_1280

News

Movers & Shakers

ELAB

INMB

Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc. (NASDAQ:INMB).

Why Elevai Labs Stock Is Trading Higher

INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer’s Disease

Biotech

Interview

General

David Moss, CEO of INmune Bio (NASDAQ: INMB) was recently a guest on Benzinga’s All-Access.

INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer&#39;s Disease

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

APPH

APPS

BLBD

CSII

REVB

SCLX

U.S. stocks traded higher this morning, with the Dow Jones jumping around 250 points on Thursday.

The Dow traded up 0.75% to 34,204.99 while the NASDAQ rose 1.15% to 12,047.28. The S&amp;P 500 also rose, gaining, 0.75% to 4,148.69.

Dow Jumps 250 Points; US Jobless Claims Increase Last Week

INmune Bio Inc

INmune Bio Announces 24-Month Stability Validation Of XPro For Phase III Readiness And Commercial Supply Chain Modeling & Development Of Novel Immunogenicity Assay

<a href="https://www.globenewswire.com/Tracker?data=gvmWdStBEy_CgwJgL3vp4BFwUVPWfjNYbo2LmCMnVLo3jq3Sq67wpsbOWvACZSCfVhcz8-9M8ZgH72dpbzO2nDBHNM-KQqfifbkmAMZkbss=">INmune Bio, Inc.&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today&nbsp;announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price &nbsp;that include an acceleration clause upon positive top-line data in the Company's Phase 2 Alzhzimer's Disease program (as further described &nbsp;below).&nbsp; The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering. The offering was priced at the market based on the Friday, April 19th&nbsp;Nasdaq consolidated closing bid price of $8.32 per share. The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date"). The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 24, 2024, subject to the satisfaction of customary closing conditions. Members of management and the Company's board of directors and certain key employees participated in the offering and will pay a combined offering price for the common stock and warrants of $8.445 per share and warrant, and &nbsp;in the case of officers and directors that participated in the offering, if the warrant termination date is on a blackout date then the officers and directors will have an additional 60 days from the termination of the blackout date to exercise the warrant. &nbsp;
The Company intends to use the net proceeds for completing the ongoing Phase 2 trial (AD02) in patients with Early Alzheimer's Disease (AD) using XPro&#x2122; and the metastatic castration-resistant prostate cancer (mCRPC) Phase 1 trial using the INKmune technology.&nbsp;&nbsp;
LifeSci Capital is acting as sole placement agent for this offering.&nbsp;&nbsp;&nbsp;

Offerings

INmune Bio Inc. Raises ~$4.8M In Gross Proceeds Through Registered Direct Offering With Officers, Employees And Directors Purchasing ~20% Of The Offering

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer
Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=GCytWNTcYVaSYNhadgCBTNreZuO9eKl_xHmpkRZtYqs82e-3IMHpteVkDi_kxvMML5XoFqAEa92C5-mYrJW2x2ZOICsoNSw4Uztj9oIi_xQ=">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).&nbsp; INB03 is shown to decrease T cell and macrophage immune checkpoint proteins (PD1, TIGIT, LAG3, CD47 and SIRPa) in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion (MUC4, SNAIL and Vimectin).&nbsp; The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
The poster, titled, "INB03: a new immune checkpoint inhibitor that reprograms macrophage polarization, boosts ADCP and reverts T-cell exhaustion markers" outlines the use of human macrophages and T cells in a MUC4+HER2+ syngeneic breast cancer model to demonstrate that the combination of INB03 with an anti-HER2 antibody 4D5 has five distinct effects on the tumor biology, which results in decreased tumor growth (p&lt;0.001).&nbsp; These include: &nbsp;
i.&nbsp; &nbsp; &nbsp; &nbsp;a decrease in MUC4 expression
ii.&nbsp; &nbsp; &nbsp; a 3-fold increase in T cell infiltration
iii.&nbsp; &nbsp; &nbsp;polarization of tumor macrophages from M1 (immunosuppressive) to M2 (anti-tumor macrophages)
iv.&nbsp; &nbsp; &nbsp;a doubling of antibody dependent cellular phagocytosis (ADCP) and
v.&nbsp; &nbsp; &nbsp; a decrease in the expression of innate immune checkpoint proteins (CD47 and SIRP-a) and T cell checkpoint proteins (TIGIT, CTLA-4, PD1 and LAG-3)
In the study, the increase in T cell infiltrate did not occur unless both anti-HER2 and INB03 immunotherapy were used in combination.&nbsp; Decreases in T cell and macrophage immune checkpoint proteins were caused by INB03. All changes in immune parameters are p&lt;0.05 unless otherwise stated.&nbsp; The authors concluded that INB03 enhances the M1-like phenotype and reprograms already-polarized pro-tumoral M2-like macrophages to antitumoral ones.&nbsp; Further, it promotes ADCP against HER2+ tumor cells by downregulating the ADCP inhibitory axis CD47-SIRPα-B7H4 in vitro.&nbsp; Finally, the addition of INB03 to 4D5 treatment promotes T cell infiltration to the TME and downregulates immune checkpoint molecules and T cell exhaustion markers in vitro and in vivo.&nbsp; The authors speculate that these effects could avoid tumor immune evasion to anti-HER2 targeted therapies by reinvigorating the immune infiltrate. The poster can be found on the Company's web site.
A second poster, titled, "MUC4 is a biomarker of metastasis in TNBC and its downregulation by blocking soluble TNF prevents metastasis in combination with immunotherapy," studies the importance of MUC4 expression in TNBC survival.&nbsp; Approximately half of women with TNBC express MUC4.&nbsp; Overall survival of women with MUC4 expressing TNBC is dramatically worse (p&lt;0.005) with almost a 5-fold increased risk of death (p&lt;0.018). MUC4 expression in the tumor negatively correlated with fewer Tumor Infiltrating Lymphocytes (TILs, p&lt;0.003), PD-L1 (p&lt;0.001) and Ki67 (p&lt;0.036) expression.&nbsp; &nbsp;In human TNBC cell lines, INB03 decreased the expression mesenchymal markers of invasive capacity, MUC4, SNAIL and Vimectin, and decreased activity in an invasion assay (p&lt;0.01).&nbsp;
In a murine LMM3 model, treatment with the combination of INB03 and anti-PD1 checkpoint antibodies dramatically decreased lung metastasis with no animals receiving combination therapy having &gt;3 lesions compared to 40% of control animals (p&lt;0.05).&nbsp; The authors concluded: i) MUC4 expression is an independent biomarker of poor overall survival and is associated with an increased risk of metastasis in TNBC patients; ii) MUC4 is inversely correlated with TILs, and is associated with tumors with low proliferative rate (Ki67&lt;30%) and negative PD-L1: it would be useful to identify tumors resistant to chemotherapy and immunotherapy; iii) TNF blockade decreases MUC4 expression, mesenchymal markers and reduces invasive capacity in TNBC cell lines; &nbsp;iv) soluble TNF blockade in combination with anti PD-1 antibody prevents the establishment of lung metastases in a preclinical model of TNBC.&nbsp; They further propose soluble TNF as a new target for the treatment of TNBC, and MUC4 as a predictive marker to guide a combined treatment with selective sTNF neutralization with immunotherapy. The poster can be found on the Company's web site.
Dr. Schillaci, senior author of the study, proposes INB03 is a new class of immunotherapy called a pan immune checkpoint modulator in MUC4 expressing breast cancer.&nbsp; INB03 isn't a selective immune checkpoint inhibitor targeting a specific immune checkpoint protein; rather, it downregulates all immune checkpoint proteins present on both T cells and macrophages. "Soluble TNF, secreted by cancer cells, shields tumors from immune attacks by altering the tumor microenvironment, rendering the patient's immune response ineffective and fostering resistance to immunotherapy. Through extensive research, we have unraveled the mechanisms underlying the tumor protecting role of soluble TNF which causes tumors to proliferate. Translating these findings into targeted strategies for high-risk breast cancer, we can devise a precision medicine approach to counteract soluble TNF's effects, reversing therapy resistance, preventing&nbsp; metastasis,&nbsp;and empowering the immune system to combat tumors effectively," said Dr. Schillaci
"Dr. Schillaci has shown that MUC4 expression in high-risk breast cancer subtypes is a predictor of resistance to therapy due to an unfavorable immunobiology of the TME and increased metastatic potential that is driven by soluble TNF," said RJ Tesi M.D., CEO of INmune Bio. "Neutralization of soluble TNF changes a resistant tumor biology into one that is more favorable.&nbsp; &nbsp;
All of the individuals involved in this project share the belief that prospectively determining MUC4 expression in high-risk breast cancer subtypes will guide therapy decisions and significantly impact patient outcomes."
The posters will be presented at AACR on April 8:
PO.IM01.02 - Immune Checkpoints and Inhibitory Molecules 1 9 am
INB03: a new immune checkpoint inhibitor that reprograms macrophage polarization, boosts ADCP and reverts T-cell exhaustion markers by Sofia Bruni, Maria Florencia Mercogliano and Roxana Schillaci
PO.TB04.02. Biomarkers and Expression Differences in Metastatic Progression 1.30 pm
MUC4 is a biomarker of metastasis in TNBC and its downregulation by blocking soluble TNF prevents metastasis in combination with immunotherapy by Mauro, Florencia; Bruni, S; Dupont, A; Inurrigarro, G; Figurelli, S; Barchuk, S, Lopez Della Vecchia, D; Cordo Russo, R;Gil Deza, E; Mercogliano, M; Schillaci, Roxana
As this science is presented at AACR, the Company plans to expand its business development efforts in search of the right partner to advance the clinical development of a combination therapy with INB03.&nbsp; "We believe these findings reflect novelty and inventive step, and further support the expansion of our evolving patent portfolio covering INB03 for oncology indications, in particular, use of INB03 to target soluble TNF in combination with antibodies and other anti-cancer therapies," said Joshua Schoonover, General Counsel of INmune Bio. "Through our collaborations with academic and other research institutions, such as Dr. Schillaci's lab at CONICET, INmune Bio has learned much about INB03, including its effects on tumor biology, which enables us to explore a number of cancer treatment indications and commercial applications of the drug, and further supports partnership efforts with the goal of improving the efficacy of certain anti-cancer therapies by combining them with INB03." Interested parties should inquire with the Company for more information about available partnering opportunities.
About INB03
INB03 is a DN-TNF inhibitor that neutralizes soluble TNF (sTNF) without affecting trans membrane TNF (tmTNF) or TNF receptors.&nbsp; Compared to currently available non-selective TNF inhibitors, INB03 preserves the immune response to cancer by decreasing immunosuppressive cells in the TME including TAM and MDSC while promoting recruitment of anti-tumor immune cells including cytolytic CD8+ lymphocytes, NK cells and anti-tumor macrophages.&nbsp; INB03 has completed an open label dose-escalation Phase I trial in patients with advanced cancer.&nbsp; In that trial, INB03 was found to be safe and well tolerated - no dose limiting toxicity was found.&nbsp; INB03 decreased blood biomarkers of inflammation in patients with advanced cancer.&nbsp;

INmune Bio Inc. Presents Data On INB03's Role As An Immune Check Point Modulator In The Treatment Of High-Risk Breast Cancer At AACR 2024

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
INmune Bio missed estimated earnings by -7.000000000000001%, reporting an EPS of $-0.47 versus an estimate of $-0.44.
Revenue was down $69 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.07 which was followed by a 4.0% drop in the share price the next day.

To track all earnings releases for INmune Bio <a href="https://www.benzinga.com/quote/INMB/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INmune Bio: Q4 Earnings Insights

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.44) by 6.82 percent. This is a 46.87 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $28.00 thousand which missed the analyst consensus estimate of $40.00 thousand by 30.00 percent. This is a 71.13 percent decrease over sales of $97.00 thousand the same period last year.

INmune Bio Q4 EPS $(0.47) Misses $(0.44) Estimate, Sales $28.00K Miss $40.00K Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHV

ACNT

AFMD

AONC

AREC

ATAT

AXDX

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DARE

DLPN

DNMR

DOOO

DRIO

DTST

DYAI

FORA

GROY

HSDT

IMCC

IMNN

INLX

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SMTC

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

XXII

ZVRA

Earnings Scheduled For March 28, 2024

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that INmune Bio will report an earnings per share (EPS) of $-0.44. 
INmune Bio bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.07, which was followed by a 3.82% drop in the share price the next day.
Here's a look at INmune Bio's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.41</td>
<td>-0.40</td>
<td>-0.02</td>
<td>-0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>-0.36</td>
<td>-0.36</td>
<td>-0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-10.0%</td>
<td>4.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711562474_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of INmune Bio were trading at $11.88 as of March 26. Over the last 52-week period, shares are up 99.42%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/INMB/earnings">To track all earnings releases for INmune Bio visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of INmune Bio's Earnings

Patients with Alzheimer's Disease show improvement in brainwaves following 4 weeks of XPro&#x2122; therapy.
Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) --&nbsp; <a href="https://www.globenewswire.com/Tracker?data=owEG-ybVR9W3s84V7ENafSvHFhYHAIo_2e31OB53lR_mvYb5ShRw1Y2bIq2zE3wMvW8tIa0NDECTc5jUkrsyrmSambaKznkac9a3ZkpHRZEMN1QJA8uAQTcpnHt6K9AO_zz76sw289DDUSNQEMN5NNDiJuZyWVT-T_hcR9uOdcyAJrBAmVrZi0DlxgSeyDxCaqoparS3qhVNponVNNeX4zlBkErN1lny07OcdLdt7ZkyoJpdM4nr6SygWNqAKzhULzelYAnqzoXnxvPwG25zhbAogxn8SM_PnOObQKyOA4a_Y5wK31vgrZ1vZJ-8Bif-8i8aKEe1IjdzcfgLsMhhaT9GzOCuGF9mgXHX3POrKepVl5k4WDxmiehg7_aYfIgfrxlRd2mvZqPaQxCumodkRip5siyoC1F1KOdUVutwOMTB9Z-mzj-f4hpOehcTWcuQajo4af16MMW2hLWXRouG-A==">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>)&nbsp;(the "Company"), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer's Disease treated with XPro&#x2122; for four weeks.
Patients who received weekly XPro&#x2122; treatment for four weeks had a statistically significant increase in Alpha wave frequency and power (p&lt;0.05). Reduced Alpha power is linked with cognitive decline and the progression of Alzheimer's Disease. Alpha waves represent synchronized brain network activity that&nbsp;are essential for internal functions like mental arithmetic, short-term and working memory, and visual-spatial mental imagery exercises. &nbsp;In individuals with AD, Alpha wave power is diminished due to the breakdown of brain networks associated with degeneration.
"Functional benefits are the true benchmark of a drugs biological efficacy, and these promising findings are part of a larger narrative that's still unfolding," stated CJ Barnum, PhD, VP of Neuroscience at INmune Bio. &nbsp;"We are committed to extensive research, drawing from our Phase 2 placebo-controlled trial to substantiate these findings."
The seven patient pilot study in patients with moderate to severe AD sought to evaluate the utility of EEG as a functional biomarker of target engagement in evaluating the effects of XPro&#x2122; (XPro1595;&nbsp;pegipanermin), a next generation dominant-negative inhibitor of soluble TNF, in AD patients. These positive results support and add to the findings of the Phase 1 study in patients with AD that showed XPro&#x2122; treatment reduced biomarkers of inflammation and improved biomarkers of neurodegeneration, synaptic function and improved brain microstructure and promoted remyelination. The extent to which these biomarker changes impact cognition in patients with Early Alzheimer's Disease is currently being assessed in our ongoing randomized, placebo-controlled Phase&nbsp;2&nbsp;trial.
EEG, long considered a gold standard in objectively measuring brain activity, provides valuable insight into neural connectivity. Neurological research has consistently highlighted a progressive decline in alpha band power and frequency in individuals with MCI and Alzheimer's disease. EEG's capability to assess brain function makes these findings particularly noteworthy for INmune Bio's novel treatment strategy. The use of EEG as a biomarker for brain function and its potential as a regular measure in clinical trials was facilitated by Cumulus Neuroscience's innovative, FDA approved, portable EEG device.
"It is unprecedented to continuously monitor brain function at this scale. Our goal is to bring reliable, clinic-level brain function measurement into the comfort and familiarity of a patient's home," remarked Brian Murphy, Ph.D., Chief Scientific Officer of Cumulus Neuroscience. "The work highlights the untapped potential in utilizing task-synchronized EEG throughout the drug-development process in patients with Alzheimer's disease, which could revolutionize how clinical trials are conducted and treatments are evaluated." &nbsp;
Echoing this sentiment, Dr. Barnum emphasized, "Our work with Cumulus Neuroscience is forging new paths in Alzheimer's research, by empowering us with the ability to observe&nbsp;real-time effects of XPro&#x2122; on brain function directly within patients' everyday lives."
About EEG and Alpha Band Power in AD
EEG is the gold standard for measuring brain activity; informing on how well neurons are connected within the brain. Quantitative EEG is reported by the frequency and magnitude of the electrical signal. The frequency of the EEG is categorized by bands that correspond to distinct brain activities and states whereas the magnitude measures how active the neurons are within each band.
The alpha band power, defined around the 8 to 12 Hz frequency band, increases during internal tasks such as mental calculation, short-term and working memory or visual-spatial mental imagery exercises (Vaitl et al., 2005; Klimesch, Sauseng and Hanslmayr, 2007; Palva and Palva, 2007; Lutz, Dunne, and Davidson, 2012). It broadly reflects coordinated network activity in the brain and is expected to be reduced by the "disconnection" of networks seen in neurodegeneration.
In the context of natural aging, alpha power magnitude and frequency has been observed to reduce over the lifespan (Klimesch, 1999; Scally et al., 2018) and positively correlate with individual level of cognitive performance among a group of people of a similar age (Clark et al., 2004). In diseased populations, there is broad evidence connecting a fall in alpha power and frequency to cognitive decline and disease progression (Babiloni et al., 2020; Lejko et al., 2020). Reductions in alpha power and frequency are also associated with traumatic brain&nbsp;injury and have been observed to increase during recovery (Ianof and Anghinah, 2017; Conley et al., 2018).&nbsp; Specifically, global reduction in alpha power and frequencies are observed in MCI (Mild Cognitive Impairment) patients compared to healthy older adults, and progressive MCI is characterized by lower resting alpha power and frequencies compared to stable MCI (Lejko et al., 2020). Longitudinal studies in AD patients have also reported lower magnitude and frequency of alpha rhythms after yearly follow-up (Babiloni et al., 2020, 2024).

INmune Bio Reports Significant EEG Improvement In Alzheimer's Patients Treated With XPro

INmune Bio Announces FDA Removal Of Clinical Hold For Alzheimer's Disease Program

- SEC Filing
&nbsp;
On January 16, 2023, Elevai Labs, Inc., a Delaware corporation (the "Company"), entered into a License Agreement (the "License Agreement") with INmune Bio, Inc., a Nevada corporation ("INmune"). Under the License Agreement, INmune granted the Company certain worldwide exclusive and non-exclusive license rights to develop, manufacture, and commercialize INmunes's EMx technology, ("EMx") a proprietary equipment, processes and consumables useful for isolation and current Good Manufacturing Practice ("cGMP") manufacture of human umbilical cord derived mesenchymal stromal cells ("hUMSCs",) for a period of ten years from the effective date of the License Agreement (collectively, the "Field").
Pursuant to the License Agreement, the Company will make an upfront payment to INmune as a technology transfer fee with scheduled payments six months after the effective date of the License Agreement and upon completion of the transfer of EMx. In addition, Elevai will pay INmune (i) a final technology transfer fee two years after the effective date of the License Agreement, and (ii) a capped nominal royalty on the sale of licensed topical cosmetic products that are manufactured using EMx. After the Company's first successful manufacturing that utilizes the Field, the Company has agreed to supply INmune with hUMSCs at a price pegged at a fixed percentage above the actual cost for the Company to produce them.
&nbsp;
Unless earlier terminated, the License Agreement will remain in effect on a licensed product-by-licensed product and worldwide basis until the expiration of the License Agreement. Either party may terminate the License Agreement for insolvency of the counter-party, or material breach by the other party within the time period specified in the agreement.
&nbsp;

Contracts

On Jan 16, Elevai Labs Inc Entered Into A License Agreement With INmune Bio, Inc.; INmune Granted The Co Certain Worldwide Exclusive And Non-Exclusive License Rights To Develop, Manufacture, And Commercialize INmunes's EMx Technology

Elevai Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology <a href="https://www.benzinga.com/news/earnings/24/01/36642878/dow-dips-200-points-goldman-sachs-earnings-top-views">licensing agreement with INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>).</a>
The Details:
The<a href="https://www.benzinga.com/pressreleases/24/01/g36640266/elevai-labs-inc-acquires-worldwide-license-agreement-for-proprietary-stem-cell-manufacturing-techn"> licensing agreement</a> grants Elevai a license to use INmune Bio&#8217;s proprietary &#8220;EMx&#8221; technology that enables Elevai to manufacture current Good Manufacturing Practice (cGMP) grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed topical cosmetic products sold in the medical aesthetics skincare market.
Under the agreement, Elevai will make an initial deposit for the license in two installments over six months, and a final tech transfer fee within two years of executing the agreement. As further consideration under the agreement, Elevai will be required to pay a nominal royalty on the sale of licensed topical cosmetic products that are manufactured using the EMx technology.
&#8220;Partnering with INmune Bio, Inc. aligns perfectly with our mission to pioneer innovative stem cell exosome products. Their understanding of efficient human stem cell isolation and large-scale manufacturing provides us with a remarkable opportunity to expand our manufacturing capabilities, expand our product portfolio, and make a significant impact in the market,&#8221; stated Jordan R. Plews, Ph.D., CEO of Elevai Labs.
Related News: <a href="https://www.benzinga.com/news/24/01/36614767/whats-going-on-with-lucid-group-stock">What&#8217;s Going On With Lucid Group Stock?</a>
ELAB Price Action: According to<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, Elevai Labs shares are up 7.6% at $1.84 at the time of publication.
Image: Mohamed Hassan from Pixabay

ELEVAI Labs Signs Exclusive Worldwide Manufacturing Agreement And License Agreement With INmune Bio Granting ELEVAI A License To Use INmune's EMx Technology

INKmune&nbsp;is a biologic therapy given as out-patient therapy&nbsp;without the need for pre-medication or cytokine support.

Health Care

INmune Bio Dosed The First Patient In The Phase 1/2 Trial Of INKmune In Men With Metastatic Castration-resistant Prostate Cancer

Enrollment in the Company's Phase II study using XProTM to treat patients with Alzheimer's Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial.
In the US, the previously identified clinical hold issues have been successfully addressed however the Phase II study remains on clinical hold pending additional information on long-term stability which the Company will provide before the end of 2023.

INmune Bio On Track To Complete Enrollment Of Phase II Clinical Trial In Patients With Early Alzheimer's Disease And Biomarkers Of Inflammation In 2024; FDA Said U.S. Phase II Trial Remains On Full Clinical Hold Pending Additional Information Request

<a href="https://www.globenewswire.com/Tracker?data=rgqPHplK3lC3LaQwqTK07vKIZwsSE8WGHx610HinF38ScqiHz_mdFCB0pInwTpH0QKwbMsrLaGOth6cqBwrUK48sibtZ-pV4efJN3Vh2UpeHwDLlw8G1ANLXen0yEUCyeQnmM3ktg4KFeqzwZJmXeZ0MXCoRhDu9ajQAJ8H62QOpAFGSqbKl1m7XtSdwzJOrTJfspG6ijLilsfaqeE1ijZLr2pQoQxsICU7Hg1RYuBNDxy7jh88td6OZmsZfV3hEkdJbpJWXxCmJwQpZOms7WwF0BE7gVXA_wYA3Q4TYOxK4yAJm5OFDzaxH1MfNZwi4G-1wW_YpXiLE4HAnrTE5RU-VYRimpr6ms_cXyvJ9obqUYHCs7jhuKWS02cJ2kVe8WPOjbQ8qX855JVKPLoeHFRjkv4fkydLLPf65rp5zkcCzhDRi7WfaNdG31iksrlAz342t6nOCXSCzplQqG5dfP1N4aFvps5wWrsjjDl_0wJdfNSC5_0qaweka9QSoDRyEs8yootuctvf6z85ky_16BRQcVVH4gG2TQsYCDQpGhmjwPXKIL2OP7RDxzORWZfx6kDLml6uCCUCyr1ik--AIyl4R5m4P_ELVOZfHZ9kKNOF8HqopR5EYfeTfGLemtuQaZoHyhJ-s-peFj2Wee11kuipvZF72--hO6RAGLs1QKI2cMNU_FZScUNSFyTzWcv-x97umaskGHJsQ6-CmgdvdmPfaLNIyGfsf-DKDqZH4zMA=" target="_blank">INmune Bio, Inc.&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the &quot;Company&quot;), a clinical-stage immunology company focused on developing treatments that harness the patient&#39;s innate immune system to fight disease, is&nbsp;presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2. Roxana Schillaci, Ph.D., of Instituto de Biolog&iacute;a y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 46th&nbsp;annual San Antonio Breast Cancer Symposium, which runs from December 5 to 9.

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

INmune Bio Has Received European Medicines Agency's Authorized Decision In France And Spain For Phase 2 Clinical Trial Of XPro For Early Alzheimer's Disease

The Company received a cash refund of approximately $2.8M USD pursuant to an <a href="https://www.globenewswire.com/Tracker?data=w-ge5ehUp0eMNrik9vDiobVGeCIAPRlYcvGPXMpL3TRsXOBABxwL6qnM3ZQoqAJMndMaLEwphdJh4AjIm4TzKLs2xy9Fa6nvc8txgQTbpa9husiVDrbxcAaAx10v6RambrG2uicYY22tJPKOKLPLJCO1ZD2nVibOhMYj5PudMsPBGOUtdc2LZFx71C3JQnThQjGbzbeCPkS3uQ3BIeSw8A==">Australian Research and Development Tax Incentive</a>.
Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=u71D83kIO1SZEyaBiWP3-ier8H2UgKnvK11bzM9OO280ExYL33_DopmvUHPIPcQFRNDcU2uOwDtWATgypvT8sSR6tl2LouY7FV2dP1QL8lDljwhO6De4rwldRnesyWIQZK6OXWB0FhHP5kxvq7lwQyc_1CU08pG-gjRC8lVVf52Lqx-V7PZDAyXFVxrSv6k8RFRBofskjrHuQ23fEkcx1ZpYJXO7TTOWAinR93fBwn70CgMq8Z-YGjJ0b6bF01KNKLg3rUv85fX3YBfjIs4zNZkCC7N5EbbgkhRuRCu7gg3m2CNDNLeJoyN1o_sx2hULMunfx5J6vL07iNSPrmHQi08WDuxBzws2rEoEZIL0MBdQmiB-DvaFu2L8lZKhH519_pqGqYmRIpMTPGuaL4OWF-tcOJ6OiyUFFOPiev52A2_Eztk_5zIyslIBWT1dUqHwfEgbBkZj62Y0joeDizeqjQ==">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage immunology company dedicated to &nbsp;advancing treatments that leverage the patient's innate immune system to combat disease, has received acceptance of a Clinical Trial Application (CTA) under EU Clinical Trials Regulation to initiate a Phase II trial in Early Alzheimer's Disease (AD) with XPro&#x2122; in Poland. Additional regulatory approval for the Phase II AD clinical trial is expected from at least two to potentially six more EU countries in the upcoming months. &nbsp;The EU approval is part of the Company's international clinical development strategy for XPro&#x2122; in patients with early AD. The trial is currently enrolling patients in Australia, Canada, and the United Kingdom.
The Phase II clinical trial is a global, multi-center, randomized clinical study in patients diagnosed with early Alzheimer's disease who have biomarkers of elevated inflammation. In a prior Phase I open-label trial, INmune Bio met all primary and secondary endpoints. Patients with AD who received XPro&#x2122; demonstrated notable decreases in neuroinflammation, enhanced axonal integrity, and improved synaptic function. Employing advanced MRI imaging techniques enabling a "virtual biopsy" of the brain, treatment with XPro&#x2122; demonstrated improvements in the structural integrity of both gray and white matter in the brain.
"We are delighted with the addition of clinical sites in the EU. Countries were selected based on their previous experience in Alzheimer's disease research and their interest in novel therapies,"&nbsp;said RJ Tesi M.D., CEO of INmune Bio.&nbsp;"Broadening the clinical presence in the EU serves dual purposes.&nbsp; First, it addresses the near-term objective of completing enrollment of the Phase II trial. &nbsp;Additionally, the initiation of sites in the EU establishes the groundwork for realizing our long-term goal of conducting a global Phase III trial."
The Company also recently received a cash refund of approximately $2.8 million pursuant to a research and development tax incentive from Australia. The Company will use the rebate to reinvest in its clinical programs.
"We are delighted with the ongoing receipt of R&amp;D rebates from research-friendly jurisdictions like Australia. These funds provide a non-dilutive funding source, allowing INmune to reinvest in expanding recruitment and enrollment not only in Australia and Canada but also in our newer locations in the U.K. and the EU," remarked David Moss, Chief Financial Officer.
About XPro&#x2122;
XPro&#x2122; (XPro1595, pegipanermin) is a next-generation selective inhibitor of tumor necrosis factor (TNF) that is currently in clinical trials and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro&#x2122; could potentially have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation, decreasing neurodegeneration while improving synaptic function and promoting remyelination. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit<a href="https://www.globenewswire.com/Tracker?data=8S-O0Ka7dPwz2lRRqwJPzcohLKD9lF-UxB0NtUJaJ8q_pCN11M_xtAbBblENGf17tAKP8b4DdCv_m6EXiKTkDa59r63JGTqgKF4AYb8hAztjfsKjXm2mnzyGwiCzEBykLNqxBjIxb7I8QYGr3Q5f-d6XGxScH8QusTUQWAbZzH6mrZoTNYdrETAj703owUFSwlVVwEzN_vjjOwjeEMa7sFyte3qj7vKf-o-R7tS2sFlTsMPP9f_Cm8w87IBGgeEGgtxfQFFqz8_kgRUIYvwK_57zDoaCIZhkx3P6m87okEOPsQpZAYcbuQXrVjvR5gC8LbJZgRsjyQZ3kNuVi3BX9pJoUIRpVyNdcvKtlAkwOPyt7DX-3u5qU9-1er9lDhBQ">this section of the INmune Bio's website</a>.

INmune Bio Inc. Announces Expansion Of Phase II Clinical Trial For Alzheimer's Disease In Europe; The Company Received A Cash Refund Of ~$2.8M Pursuant To An Australian Research And Development Tax Incentive

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.41) by 17.07 percent. This is a 11.63 percent decrease over losses of $(0.43) per share from the same period last year. The company reported $43.00 thousand in sales this quarter. This is a 56.12 percent decrease over sales of $98.00 thousand the same period last year.

INmune Bio Q3 2023 Gaap  EPS $(0.48) Misses $(0.41) Estimate, Sales $43.00K Down From $98.00K YoY

INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune&#x2122; therapeutic composition.
Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=71SUrxYUFxC2Xb-0BWLXyeUu2UMyRvjT9XcV7JNeQCSUSKN5vOaERKrMEV96Bbn2w4MKrlEy3BmeS6e1Nsaxuvwbv2LtjwLOCBCugjvBwGSH2KekhOpBEIbkUm8CdBHlP3n0bg5eFkhYP0LCLIAeQZMo5QLjqiYHICZ3CtH3vD226QfqqGN2NOXzG3LZyJ46WXR60b4i_o6eVJ9qrH0sMtgHoevKofl3gacp1Ze-MwJdEoS2j-w3xL7tsFRpG3yhG0xcp5iHKxXqSwPII8XNbGaPIJz5h-8UFwRuzahHScwx5mHv-qjeEXktF_XJrRRA7CUuiUcJzfPCLfmuoLw92kH0FznyZy0Ly2tAWCVfP_UY7qTKquj6G4kEYeMXGeSP8NjMb7JwtOE6goR9MzwVgKZWer2eyEmF0urcv-Libmcrw24D0MtE04clr6nrFn2xxdwOEGRM4-Ilsrow6cSNwYmh7Y5kJzXgMNztamZzTwSNW1CNFGEydCqB6ggypbXBYItZbjItVSE21QooxdI3WTEfSVbB6xow0opwEzj1hYMYG5z2ZFq2v5Jya7LdHxA1qWqKywCvClU4LiKf4mKCuISGRM9-xjfG76Wq_CkT8-wpMqiAQtjCc_Yg8EsgrDzkeRrPsXEI6CWTAOni8BZ8dEcQyoECFZKGOIj_Hot6gMt-Nf1X3QtXCbgqgTXh3bExbFpMqiJUIgWNEuNvzJ2-Y67zj1exMypnbXcx30vhRO4=">INmune Bio, Inc.</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced an update regarding the company's patent covering its proprietary cell line, "INB16", as well as the therapeutic composition comprising replication-incompetent INB16 cells known as "INKmune&#x2122;" and methods of treating cancer by administering INKmune&#x2122;, with a goal of achieving in vivo priming of natural killer (NK) cells to enhance the ability of a patient's own NK-cells to effect cancer surveillance, recognition, and killing.
In the written opinion for the international patent application titled, "HUMAN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINE &amp; APPLICATIONS FOR TREATING CANCER," an examiner from the International Search Authority at the United States Patent &amp; Trademark Office, authorized by the World Intellectual Property Organization under the Patent Cooperation Treaty, issued a favorable patentability opinion with respect to novelty, inventive step and industrial applicability of all claims and concluding that the application contains patentable subject matter. The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells ("INKmune&#x2122;") and methods of treating cancer in patients by administering INKmune&#x2122;.
"Patents covering novel cell lines are somewhat rare in practice and form a very small number of total patents issued,"&nbsp;said Joshua Schoonover, Esq., in-house General Counsel for the Company. "The company is exploring several potential commercial applications of the INB16 cell line, including uses in cancer research, as well as therapeutic uses, such as applications for treating various cancer indications, or for enhancing other NK cell products to gain advantages, such as improved avidity or memory-like functions."
The Company intends to leverage the favorable written opinion under the <a href="https://www.globenewswire.com/Tracker?data=iKgAvoQnSj9ONBXObip2W6JNT3XyKcKTW56H0MqMW7mV6jdSTgWFp-23EEY5TVErNTS6mEbepf-uWWrqxMpw_8qSOLr_vlcRQREQa-azkde9aI4hdnM-MF8NSyb8YX_Q93LEQCz58rN8oaBsRBvGtLE_LDFd26n7F2ISQCKj3hqU4WgzfOpMgQcoOju2etnpkSbH6OHgrnQrmVIPUkxnsA==">patent prosecution highway</a>, a program offered by the USPTO, EPO and other participating patent offices to accelerate examination and ultimately patent issuance for inventions receiving favorable opinions received from certain patent authorities, including WIPO.
INB16 is a tumor cell line which is relatively insensitive to killing by natural killer (NK) cells from healthy donors and from patients. However, it carries molecules on its surface which bind to critical activating ligands on resting NK (rNK) cells and, when an rNK cell binds to INB16 the rNK becomes primed by the activating ligands. One of the key molecules on the INB16 surface is called CD15 and this binds to a ligand on rNK cells called CD2. Virtually all rNK in the blood express CD2. The Company has shown that this CD15-CD2 interaction is critical and has further mapped the intracellular signaling cascade that it activates. During the next 16 hours after INB16 binding, the rNK becomes "primed" to form what is called a "tumor-primed NK cell" – TpNK. These TpNK have the characteristics of memory-like NK cells described by other groups and which are produced in the lab by priming with a cocktail of inflammatory cytokines (IL12/15/18). TpNK are a type of mlNK and can kill tumor cells that are resistant to rNK cell-killing. This means that they can kill a wide range of clinically relevant cancers and leukemias. In addition, the Company's in vitro data shows that TpNK cells are able to overcome the immunosuppression of hypoxia and regulatory cells in an active Tumor Microenvironment of solid tumors. The Company is extending these findings to show that INKmune-primed NK cells also overcome immunosuppressive cytokines in the TME as a result of the NK differentiation into a memory-like cell.
While INB16 can generate TpNK cells in vitro, it cannot be used to treat NK cells in the blood of patients without being treated to prevent it from further proliferation. To overcome this, the Company uses novel methods to make the INB16 unable to replicate and created a "replication-incompetent cell," which forms a basis of the biologic called "INKmune&#x2122;." The Company has safely treated five patients with hematological cancers and shown that INKmune&#x2122; treatment converts patient's normal resting NK cells into potent memory-like NK cells much like those that can be produced in vitro. More patients are awaiting trial enrolment. Administration of INKmune may be the only way to create mlNK in vivo because the cytokine cocktail used by others would be too toxic to use as a direct treatment.
The Company opened an IND for a US trial of INKmune&#x2122; in metastatic castration-resistant prostate cancer. The first site will be initiated in the second week of November, meaning that efforts are ahead of schedule for the planned first patient treatment in this quarter. At least one other site is expected to be opened before the end of the year. A clinical batch of INKmune&#x2122; has been manufactured for the first US cohort and is ready to be shipped to a distribution center. Patients at each dose level will receive all three doses of INKmune&#x2122; as an out-patient treatment during the six-month trial. Two markers of INKmune&#x2122; efficacy will be measured – immunologic activation and therapeutic efficacy as a measure tumor response to INKmune&#x2122; therapy, using traditional biomarkers of prostate cancer tumor burden (progression-free survival, changes in blood PSA level, and tumor burden measured by bone and CT scan).

INmune Bio Inc. Patent Claims Covering INB16 Cell Line And INKmune Therapeutic Composition given Favorable Patentability Opinion By International Search Authority

SIRP-CD47 is an innate immune checkpoint known as the "don't eat me" signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis&nbsp;(ADCP). &nbsp;
Boca Raton, Florida, Oct. 30, 2023 (GLOBE NEWSWIRE) -- &nbsp;&nbsp;<a href="https://www.globenewswire.com/Tracker?data=3rLpmnc1wl62PY11WCqI7RBI8XZBqmE--vlNcwbsUDf9-g2ITUI8LCS7xZxDXzkt17e9bMfAHGju7AA4gKXrDhV9X7N-TMESC7NSs3llXAIvQsTzk4JC3wIRDcA58W3FVc8s-FdttZ9nPAFpg2W11mrK-I5UVD5dxCFtEqEQ6bdT9fqOsctULZkHNs2eH7xK4wIxT4pC_1c9VrzuDZyLaK0f-oYtAfPn87sqZHrO1gcTuPHjHcULTbdng621anvSXQq2ooPJHlVdNmtSh6Y0VFp11zLJguBxFdrSr3jLEOqT23kn5W_0LCjQHLy8Q6c_3ydFEeSh6ukdJdLUf3L_ouFTrId0EYuS6f7Uu7gE2TaJLaFWtL8g2M_zc1Ccpp00TC6xi7wswpxHO7aLNHgZIEiU1MLZ7Op0_rWf25TQat5dbF5pIL0vIxiypg1AAoqFYGykBR0ZiDoqi06nbRo4jg6RVyO4s33G7vQHYRGMsMawtJDVqYD1CWjjIFB8tox_A_zvgDqbDeWqN_0gO51WJgvp__VAIPr1F7YJuvugVl2S9V1zPL9YoQpvl7oysiM1q_kmIqgxiLKCBIT7lZoqBi4bDdxTKPPC1O14m43a9Uhp4xe1Qv_PGynsd1ob99pO_VfeuZgWbC8a1MMGJqDJwXNCoPDenpeX7COvtWHg7iBwCz3AvTaaxSQzEKY0QTE3pL8q4gXwbUlRas4VRGQ4klYFXocZbt3RZ9si1Fz1UP8=">INmune Bio, Inc.&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer. Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4.
The poster entitled "INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages," shows that INB03 is an innate immune checkpoint inhibitor working through the SIRPα-CD47 pathway to promote ADCP. SIRPα is a surface protein expressed by macrophages that binds to CD47 expressed by tumor cells. SIRPα-CD47 is known as the "don't eat me" signal that prevents phagocytosis of tumor cells and promotes resistance to immunotherapy. INB03 downregulates SIRPα expression to eliminate the "don't eat me signal" and promote ADCP. Inhibition of the SIRPα-CD47 pathway has focused predominately on targeting CD47 with anti-CD47 therapeutics. Targeting SIRPα may provide differentiated pharmacokinetic, safety, and efficacy profiles.
"Macrophages play an important role in the control of tumors, but cancer cells have developed very efficient ways to evade attack by the patient's immune system,"&nbsp;said Roxana Schillaci, Ph.D. of CONECIT and senior author of this work. "TNF promotes expression of SIRPα on macrophages that bind to CD47 on tumor cells to prevent ADCP.&nbsp; Neutralization of sTNF with INB03 downregulates the expression of SIRPα to promote ADCP that should help control tumor growth and prevent resistance to immunotherapy."
The research presented in the poster examines animal models and human macrophages. INB03 neutralizes sTNF, repolarizing tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression. In mice with trastuzumab resistant breast cancer, INB03 treatment polarizes splenic and tumor-infiltrating macrophages to M1 type macrophages that phagocytize tumor cells and decreased immune checkpoint expression (PD-L1, TIM3, LAG3) in tumor-infiltrating CD8+ T cells.
RJ Tesi MD, CEO of INmune Bio, stated that, "<a href="https://www.globenewswire.com/Tracker?data=coYkElf1NmZBS5oNIrrVjDNxV8eF15LOdMI8Y9iCVVE1dbW7iVF7h5L0YgKprUzKoUCy0Ds9aPT5xDHKOXKjXwFUNEKo-ChPg4_kDge-en8nsgrgas1JwTv1AoZqeQIkYfi8IphgekSlVVrpw_0qJiOKmc-WLTx8VicvQdYu02M=">a new therapeutic strategy</a> for treating cancer is to improve the function of tumor-infiltrating macrophages. DN-TNF has been shown to improve macrophage&nbsp;phagocytosis in models of AD, MS, DMD, and cancer." Microglia are tissue-based macrophages of the brain, while tumor macrophages are the phagocytic cells of the tumor microenvironment (TME). In disease, soluble TNF depresses macrophage phagocytic function, resulting in neurodegeneration, synaptic dysfunction, and demyelination in the brain or tumor growth and resistance to cancer immunotherapy. DN-TNF neutralizes sTNF and returns phagocytic function to normal. In neurodegenerative diseases, DN-TNF promotes microglial phagocytic function to promote remodeling and repair by decreasing neurodegeneration, improving synaptic plasticity, and promoting remyelination. In cancer, DN-TNF repolarizes immunosuppressive macrophages into tumor-killing macrophages&nbsp;and promotes ADCP. In both cases, normalizing phagocytic function should allow for therapeutic benefits.
Acronyms: DN-TNF: Dominant-Negative Tumor Necrosis Factor sTNF: Soluble Tumor Necrosis Factor ADCP: Antibody Dependent Cellular Phagocytosis SIRPα: Signal-Regulatory Protein Alpha TME: Tumor Microenviornment AD: Alzheimer's Disease MS:&nbsp;Multiple Scleroisis DMD: Duchenne Muscular Dystrophy CNS: Central Nervous System
About INB03
INB03 is a DN-TNF inhibitor that neutralizes soluble TNF (sTNF) without affecting transmembrane TNF (tmTNF) or TNF receptors. Compared to currently available non-selective TNF inhibitors, INB03 preserves the immune response to cancer by decreasing immunosuppressive cells in the TME including TAM and MDSC while promoting recruitment of anti-tumor immune cells including cytolytic CD8+ lymphocytes, NK cells and anti-tumor macrophages. INB03 has completed an open label dose-escalation Phase I trial in patients with advanced cancer. In that trial, INB03 was found to be safe and well tolerated - no dose limiting toxicity was found. INB03 decreased blood biomarkers of inflammation in patients with advanced cancer. INMB is planning a Phase II trial that uses IN03 as part of combination therapy.

Events

INmune Bio Inc. Presents Preclinical Data At SITC 2023 Showing INB03 Is An Innate Immune Check Point Inhibitor That Downregulates SIRPα

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Inmune Bio (INMB – Research Report), with a price target of $21...

BTIG Remains a Buy on Inmune Bio (INMB)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), with a price target...

Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer's Treatment Developments

Notable earnings after Thursday's close

INmune Bio GAAP EPS of -$1.67 misses by $0.02, revenue of $0.15M beats by $0.01M

INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
INmune Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/inmb-stock-quote/">INMB</a>) just reported results for the fourth quarter of 2023.<ul><li>INmune Bio reported earnings per share of -47 cents. This was below the analyst estimate for EPS of -44 cents.</li><li>The company reported revenue of $28,000.</li><li>This was 30% worse than the analyst estimate for revenue of $40,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/inmb-stock-earnings-inmune-bio-for-q4-of-2023/">INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Roivant Sciences (ROIV – Research Report) and Inmune...

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Inmune Bio (INMB – Research Report) on April 9 and set a price target of $16.00. Joe...

Inmune Bio's INB03 Shows Promise as Pan-Immune Checkpoint Inhibitor: A Buy Rating from Analyst Joel Beatty

INmune Bio: An Opportunity In The Freefall (Rating Upgrade)

INmune Bio rises 2%, on $4.5M direct offering

GDNSF

REED

ROIV

Press Releases

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program

INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with  Officers, Employees and Directors Purchasing Approximately 20% of the Offering

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay